



DT05 Rec'd PCT/PTO

08 JUL 2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GEORG BALJER et al.**Serial No.:** 10/009,059**Filed:** December 3, 2001**For:** RECOMBINANT FUSION
PROTEIN, (VACCINE)
COMPOSITION CONTAINING
THE SAME AND METHOD
FOR THE PRODUCTION
THEREOF**Examiner:****Group Art Unit:** 1644**Docket No.** 20740-242738COPY OF PAPERS
ORIGINALLY FILEDOffice of Initial Patent Examination's
Customer Service Center
Commissioner for Patents
Washington, D.C. 20231I CERTIFY THAT, ON JULY 2, 2002, THIS PAPER IS BEING
DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN
AN ENVELOPE ADDRESSED TO THE COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231.
Kimberly L. Bzdok**REQUEST FOR CORRECTED FILING RECEIPT**

Dear Sir:

The above-identified Applicants respectfully request that the following corrections
be made to the data shown in the Filing Receipt.

A copy of the filing receipt showing the requested corrections is enclosed.

Respectfully Submitted,

GEORG BALJER et al.

By:

Paul W. Busse, #32,403
FAEGRE & BENSON LLP
2200 Wells Fargo Center
90 South Seventh Street
Minneapolis, MN 55402-3901
612/766-7046

Dated: July 2, 2002

M2:20474160.01



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/009,059	02/28/2002	1644	1842	20740-242738		28	3


Paul W Busse
Faegre & Benson
2200 Wells Fargo Center
90 South Seventh Street
Minneapolis, MN 55402-3900



RECEIVED
APR 08 2002
119

CONFIRMATION NO. 4352

CORRECTED FILING RECEIPT



OC000000007775046

Date Mailed: 04/03/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

② Sylvia Franke ~~Robert Siemens, Residence Not Provided~~ ① Georg Baljer
Lindenstrasse 21, D-94574 Wallerfing/Germany Ludwig-Rinn-Strasse 15
D-35452 Heuchelheim/Germany
Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/EP00/05127 06/05/2000 ✓

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 99110759.0 06/04/1999 ✓

COPY OF PAPERS
ORIGINALLY FILED

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title

Recombinant fusion protein vaccine composition containing the same and method for the
production thereof

Preliminary Class

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).